Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pieris Pharmaceuticals stock price, quote, forecast and news

PIRS
US7207951036
A12G4Q

Price

18.33
Today +/-
+0.23
Today %
+1.43 %
P

Pieris Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pieris Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pieris Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pieris Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pieris Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pieris Pharmaceuticals Stock Price History

DatePieris Pharmaceuticals Price
8/26/202418.33 undefined
8/23/202418.07 undefined
8/22/202418.40 undefined
8/21/202418.15 undefined
8/20/202416.82 undefined
8/19/202416.88 undefined
8/16/202416.62 undefined
8/15/202416.27 undefined
8/14/202416.75 undefined
8/13/202416.41 undefined
8/12/202415.89 undefined
8/9/202415.16 undefined
8/8/202415.52 undefined
8/7/202416.46 undefined
8/6/202416.63 undefined
8/5/202416.18 undefined
8/2/202417.39 undefined
8/1/202417.08 undefined
7/31/202416.60 undefined
7/30/202416.40 undefined
7/29/202416.35 undefined

Pieris Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pieris Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pieris Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pieris Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pieris Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pieris Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pieris Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pieris Pharmaceuticals’s growth potential.

Pieris Pharmaceuticals Revenue, EBIT and net profit per share

DatePieris Pharmaceuticals RevenuePieris Pharmaceuticals EBITPieris Pharmaceuticals Net Income
2028e193.39 M undefined148.1 M undefined0 undefined
2027e17.85 M undefined-42.33 M undefined0 undefined
2026e0 undefined-28.65 M undefined-417,384 undefined
2025e0 undefined-27.15 M undefined-390,456.02 undefined
2024e6.76 M undefined-22.28 M undefined-269,280.02 undefined
202342.81 M undefined-15.84 M undefined-24.54 M undefined
202225.9 M undefined-43.47 M undefined-33.28 M undefined
202131.42 M undefined-51.83 M undefined-45.74 M undefined
202029.32 M undefined-33.92 M undefined-37.23 M undefined
201946.28 M undefined-27.16 M undefined-28.3 M undefined
201829.1 M undefined-30.83 M undefined-26.75 M undefined
201725.28 M undefined-14.59 M undefined-17.65 M undefined
20165.83 M undefined-22.76 M undefined-22.8 M undefined
20152.93 M undefined-13.68 M undefined-14.06 M undefined
20145.37 M undefined-7.2 M undefined-9.85 M undefined
201312.43 M undefined554,000 undefined66,000 undefined

Pieris Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
125252529462931254260017193
--58.33-60.00150.00400.0016.0058.62-36.966.90-19.3568.00-85.71---1,035.29
----------------
0000000000000000
0-7-13-22-14-30-27-33-51-43-15-22-27-28-42148
--140.00-650.00-440.00-56.00-103.45-58.70-113.79-164.52-172.00-35.71-366.67---247.0676.68
0-9-14-22-17-26-28-37-45-33-2400000
--55.5657.14-22.7352.947.6932.1421.62-26.67-27.27-----
0.370.370.430.520.550.660.630.680.810.931.1300000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Pieris Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pieris Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
3.6918.4729.3529.3672.63128.11104.1570.44117.7659.1726.37
0.48000.0615.552.76.791.713.315.810.57
0.070000000005.47
00000000000
0.581.332.313.261.624.574.073.586.558.456.28
4.8219.8131.6632.6789.79135.38115.0175.72127.6373.4238.68
2.442.052.162.264.035.0522.9425.9823.0320.70
00009.92000000
00000000000
00000000000
00000000000
0.0200.130.130.130.913.153.312.91.370
2.462.052.292.3914.095.9626.0829.2925.9422.070
7.2821.8633.9535.06103.88141.34141.1105.01153.5695.4938.68
1229404345545556727498
57.6184.63112.23129.35136.48189.93227.47242.67307318.53341.6
-55.96-65.81-79.87-102.67-120.31-147.07-174.18-211.41-257.14-290.42-314.96
-1,078-843-1,273-1,501-4,695-2,982-1,995-295829-25428
00000000000
0.5818.0131.1325.2311.5239.9451.3531.0350.7527.9326.76
0.281.261.062.392.453.355.81.798.614.153.37
0.560.991.743.724.868.179.497.514.8311.128.19
0.72002.2838.4636.5611.7112.8627.1221.310.36
00000000000
0.211.27000000000
1.773.522.88.3845.7848.082722.1550.5636.5811.92
4.540000000000
00000000000
0.380.330.021.4646.5853.3362.7451.8452.2430.980
4.920.330.021.4646.5853.3362.7451.8452.2430.980
6.693.852.829.8492.35101.4189.7573.98102.8167.5611.92
7.2821.8633.9535.06103.88141.34141.1105.01153.5695.4938.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pieris Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pieris Pharmaceuticals's financial health and stability.

Assets

Pieris Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pieris Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pieris Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pieris Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
0-9-14-22-17-26-25-37-45-33-24
00000002221
00000000000
-30066321-32-1630-33-48
031133455316
00000000000
00000000000
-3-5-12-1449-1-52-45-7-59-53
0000-1-1-2-20-10
0000-45-89390-2112
0000-43-712410-2012
00000000000
01,000-1,00000000000
019251544831958719
0202415448321059719
-----------
00000000000
-214100836-12847-79-21
-3.13-5.34-13.33-14.9747.8-2.77-54.93-48.63-8.61-60.97-53.99
00000000000

Pieris Pharmaceuticals stock margins

The Pieris Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pieris Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pieris Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pieris Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Pieris Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pieris Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pieris Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pieris Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pieris Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pieris Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pieris Pharmaceuticals Margin History

Pieris Pharmaceuticals Gross marginPieris Pharmaceuticals Profit marginPieris Pharmaceuticals EBIT marginPieris Pharmaceuticals Profit margin
2028e0 %76.58 %0 %
2027e0 %-237.14 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %-329.71 %-3.98 %
20230 %-37.01 %-57.33 %
20220 %-167.84 %-128.47 %
20210 %-164.97 %-145.58 %
20200 %-115.68 %-126.97 %
20190 %-58.68 %-61.15 %
20180 %-105.94 %-91.93 %
20170 %-57.74 %-69.82 %
20160 %-390.31 %-391 %
20150 %-466.61 %-479.5 %
20140 %-134.17 %-183.6 %
20130 %4.46 %0.53 %

Pieris Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Pieris Pharmaceuticals earnings per share therefore indicates how much revenue Pieris Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pieris Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pieris Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pieris Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pieris Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pieris Pharmaceuticals Revenue, EBIT and net profit per share

DatePieris Pharmaceuticals Sales per SharePieris Pharmaceuticals EBIT per sharePieris Pharmaceuticals Earnings per Share
2028e146.51 undefined0 undefined0 undefined
2027e13.52 undefined0 undefined0 undefined
2026e0 undefined0 undefined-0.32 undefined
2025e0 undefined0 undefined-0.3 undefined
2024e5.12 undefined0 undefined-0.2 undefined
202338.02 undefined-14.07 undefined-21.8 undefined
202227.94 undefined-46.9 undefined-35.9 undefined
202138.93 undefined-64.23 undefined-56.68 undefined
202043.06 undefined-49.81 undefined-54.67 undefined
201973.11 undefined-42.9 undefined-44.71 undefined
201843.83 undefined-46.43 undefined-40.29 undefined
201746.04 undefined-26.58 undefined-32.14 undefined
201611.19 undefined-43.68 undefined-43.76 undefined
20156.82 undefined-31.82 undefined-32.7 undefined
201414.66 undefined-19.67 undefined-26.91 undefined
201333.95 undefined1.51 undefined0.18 undefined

Pieris Pharmaceuticals business model

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Pieris Pharmaceuticals SWOT Analysis

Strengths

Pieris Pharmaceuticals Inc has a strong pipeline of innovative biologic drugs.

The company is known for its expertise in Anticalin protein technology, which provides a distinct competitive advantage.

Pieris Pharmaceuticals has collaborations with reputable pharmaceutical companies, enabling access to resources, expertise, and potential funding.

The company has a talented and experienced management team with a proven track record in the pharmaceutical industry.

Weaknesses

Pieris Pharmaceuticals Inc relies heavily on a small number of collaboration partners, making its revenue vulnerable to the success or failure of these partnerships.

As a biopharmaceutical company, Pieris Pharmaceuticals faces the inherent risks associated with drug development, such as clinical trial failures and regulatory issues.

The company's dependence on external funding for its research and development efforts can pose financial challenges.

Opportunities

The global biopharmaceutical market is growing rapidly, providing significant opportunities for Pieris Pharmaceuticals to commercialize its innovative drugs.

Expanding collaborations and partnerships can help the company access more resources, expertise, and potentially increase its financial stability.

With advancements in personalized medicine and targeted therapies, Pieris Pharmaceuticals can leverage its Anticalin protein technology to develop drugs for specific patient populations and unmet medical needs.

Threats

Competition in the biopharmaceutical industry is intense, with many established players and emerging biotech companies vying for market share.

Regulatory challenges and evolving healthcare policies can impact the development, approval, and pricing of Pieris Pharmaceuticals' drugs.

Changes in intellectual property laws or disputes can affect the company's ability to protect its technology and patents.

Pieris Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pieris Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Pieris Pharmaceuticals shares outstanding

The number of shares was Pieris Pharmaceuticals in 2023 — This indicates how many shares 1.126 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pieris Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pieris Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pieris Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pieris Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pieris Pharmaceuticals Stock splits

In Pieris Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Pieris Pharmaceuticals.

Pieris Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-8.98 3.2  (135.65 %)2023 Q3
6/30/2023-13.06 4  (130.64 %)2023 Q2
3/31/2023-0.14 -0.18  (-26.05 %)2023 Q1
12/31/2022-0.23 -0.11  (53.11 %)2022 Q4
9/30/2022-0.16 -0.13  (20.34 %)2022 Q3
6/30/2022-0.11 -0.14  (-24.78 %)2022 Q2
3/31/2022-0.12 -0.07  (40.32 %)2022 Q1
12/31/2021-0.31 -0.13  (56.81 %)2021 Q4
9/30/2021-0.25 -0.24  (3.3 %)2021 Q3
6/30/2021-0.27 -0.25  (7.51 %)2021 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Pieris Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

68

👫 Social

88

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pieris Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
90.14 % Citadel Advisors LLC1,189,887654,25012/31/2023
80.68 % Renaissance Technologies LLC1,065,007683,71612/31/2023
8.35 % PGIM Quantitative Solutions LLC110,200012/31/2023
78.42 % BlackRock Institutional Trust Company, N.A.1,035,080012/31/2023
740.59 % Lynx1 Capital Advisors LLC9,775,849012/31/2023
72.91 % Acadian Asset Management LLC962,358012/31/2023
7.80 % Susquehanna International Group, LLP102,971102,97112/31/2023
68.74 % The Vanguard Group, Inc.907,390-128,15012/31/2023
6.89 % Two Sigma Investments, LP90,9296,03512/31/2023
6.82 % Virtu Americas LLC90,05990,05912/31/2023
1
2
3
4
5
...
10

Pieris Pharmaceuticals Executives and Management Board

Mr. Stephen Yoder47
Pieris Pharmaceuticals President, Chief Executive Officer, Director (since 2014)
Compensation 2.06 M
Mr. Ahmed Mousa39
Pieris Pharmaceuticals Senior Vice President, Chief Business Officer, General Counsel, Secretary
Compensation 963,967
Mr. Thomas Bures48
Pieris Pharmaceuticals Chief Financial Officer, Senior Vice President
Compensation 943,561
Dr. Hitto Kaufmann52
Pieris Pharmaceuticals Senior Vice President, Chief Scientific Officer
Compensation 876,757
Mr. James Geraghty
Pieris Pharmaceuticals Independent Chairman of the Board
Compensation 136,732
1
2
3

Pieris Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Seagen Stock
Seagen
SupplierCustomer0,55-0,260,430,340,600,03
Roche Holding Stock
Roche Holding
SupplierCustomer0,330,92-0,050,14-0,110,49
Sichuan Kelun Pharm A Stock
Sichuan Kelun Pharm A
SupplierCustomer0,29-0,78-0,430,380,18-0,42
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,180,50-0,30-0,67-0,530,16
Eli Lilly Stock
Eli Lilly
SupplierCustomer-0,33-0,24-0,23-0,54-0,560,40
1

Most common questions regarding Pieris Pharmaceuticals

What values and corporate philosophy does Pieris Pharmaceuticals represent?

Pieris Pharmaceuticals Inc represents values of innovation, dedication, and excellence in the pharmaceutical industry. As a biotechnology company, Pieris Pharma focuses on advancing novel targeted protein therapeutics to improve patients' lives. Committed to scientific expertise and cutting-edge technology, Pieris Pharma strives to develop innovative solutions for various diseases such as cancer, respiratory disorders, and rare genetic conditions. With a strong corporate philosophy centered around collaboration, integrity, and patient-centricity, Pieris Pharma aims to revolutionize the field of therapeutic protein engineering and make a positive impact on global healthcare.

In which countries and regions is Pieris Pharmaceuticals primarily present?

Pieris Pharmaceuticals Inc is primarily present in the United States, Germany, and Switzerland.

What significant milestones has the company Pieris Pharmaceuticals achieved?

Pieris Pharmaceuticals Inc has achieved several significant milestones in its journey. The company successfully entered into multiple strategic collaborations, including partnerships with top pharmaceutical companies, which has enhanced its research and development capabilities. Pieris Pharmaceuticals Inc also obtained regulatory approvals for clinical trials, demonstrating the progress in its innovative therapies. The company's accomplishments include securing investments and grants, validating its potential in the biopharmaceutical industry. Pieris Pharmaceuticals Inc has consistently delivered positive clinical results and progressed its pipeline of candidates, strengthening its position as a leading player in the field. These achievements highlight the company's dedication to advancing novel therapeutics and its commitment to drive growth and value.

What is the history and background of the company Pieris Pharmaceuticals?

Pieris Pharmaceuticals Inc is a renowned company that specializes in the development and commercialization of innovative therapies. Founded in 2001, Pieris Pharmaceuticals has a rich history of pioneering advancements in the field of biotechnology. The company is dedicated to addressing unmet medical needs and improving patient outcomes through its proprietary Anticalin® technology platform. With a focus on therapeutic areas like oncology, respiratory diseases, and other severe conditions, Pieris Pharmaceuticals continues to forge partnerships and collaborations with leading industry players to bring its groundbreaking drugs to the market. This company's commitment to research, innovation, and the pursuit of scientific excellence has solidified its position as a frontrunner in the pharmaceutical industry.

Who are the main competitors of Pieris Pharmaceuticals in the market?

The main competitors of Pieris Pharmaceuticals Inc in the market include companies such as AstraZeneca, Amgen, Novartis, and Roche.

In which industries is Pieris Pharmaceuticals primarily active?

Pieris Pharmaceuticals Inc is primarily active in the biotechnology industry.

What is the business model of Pieris Pharmaceuticals?

The business model of Pieris Pharmaceuticals Inc focuses on the development and commercialization of innovative anticalin-based therapeutics. As a clinical-stage biotechnology company, Pieris Pharmaceuticals utilizes its proprietary Anticalin platform to create next-generation protein therapeutics for a wide range of diseases. The company collaborates with pharmaceutical partners to advance its drug candidates and expand their reach in various therapeutic areas, including oncology, respiratory diseases, and immuno-oncology. By leveraging its unique technology, Pieris Pharmaceuticals aims to provide targeted treatment options that address unmet medical needs and improve patient outcomes.

What is the P/E ratio of Pieris Pharmaceuticals 2024?

The Pieris Pharmaceuticals P/E ratio is -76.65.

What is the P/S ratio of Pieris Pharmaceuticals 2024?

The Pieris Pharmaceuticals P/S ratio is 3.05.

What is the AlleAktien quality score of Pieris Pharmaceuticals?

The AlleAktien quality score for Pieris Pharmaceuticals is 3/10.

What is the revenue of Pieris Pharmaceuticals 2024?

The expected Pieris Pharmaceuticals revenue is 6.76 M USD.

How high is the profit of Pieris Pharmaceuticals 2024?

The expected Pieris Pharmaceuticals profit is -269,280.02 USD.

What is the business model of Pieris Pharmaceuticals

Pieris Pharmaceuticals Inc was founded in 2001 in Freising, Germany. The company operates in the biopharmaceutical industry and develops innovative therapeutics based on the Anticalin technology. The Anticalin technology is a patented platform technology used to develop highly specific and effective medications. The company is headquartered in Boston, Massachusetts and has offices in Europe. Pieris Pharmaceuticals is listed on the NASDAQ stock exchange and had a revenue of over 35 million US dollars in 2020. The company has over 200 employees and focuses on the development of therapeutics for the treatment of cancer and inflammation. The company divides its business model into four main areas: 1. Research and development 2. Partnerships and licenses 3. Product sales and license fees 4. Financing Research and development: Pieris Pharmaceuticals specializes in developing medications for the treatment of cancer and inflammation. The company uses its patented Anticalin technology to develop therapeutic agents that provide a treatment option for patients who do not respond to conventional treatment methods, due to their high specificity and effectiveness. The company is engaged in the identification and development of new drug candidates, which are then tested in various phases of clinical trials. Pieris Pharmaceuticals currently has several promising drug candidates in development. Partnerships and licenses: Pieris Pharmaceuticals seeks partnerships with other companies and research institutions to advance the research and development of Anticalin-based therapeutics. The company has already formed several partnerships with major pharmaceutical companies such as Servier, Roche, Daiichi Sankyo, and AstraZeneca. Pieris Pharmaceuticals also grants licenses to other companies to enable their use of the Anticalin technology. These partnerships and licenses expand the market for the Anticalin technology and contribute to the further development of Anticalin-based therapeutics. Product sales and license fees: Pieris Pharmaceuticals has agreements with other companies for the marketing of its products. The medications developed by the company are licensed to these companies for distribution. Pieris Pharmaceuticals receives license fees from these companies based on product sales. Financing: Pieris Pharmaceuticals finances its research and development of therapeutics through the sale of stocks, private investors, and proceeds from partnerships and license fees. The company has successfully completed several funding rounds and raised additional funds to support the research and development of therapies. Conclusion: Pieris Pharmaceuticals' business model brings the patented Anticalin technology to market for the development of specific, effective therapeutics for the treatment of cancer and inflammation. The company focuses on sharing its expertise and technology with other companies to provide additional resources and expand the market for Anticalin-based therapeutics. Through successful financing of research and development activities, the company has added several drug candidates to its pipeline.

What is the Pieris Pharmaceuticals dividend?

Pieris Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Pieris Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Pieris Pharmaceuticals or the company does not pay out a dividend.

What is the Pieris Pharmaceuticals ISIN?

The ISIN of Pieris Pharmaceuticals is US7207951036.

What is the Pieris Pharmaceuticals WKN?

The WKN of Pieris Pharmaceuticals is A12G4Q.

What is the Pieris Pharmaceuticals ticker?

The ticker of Pieris Pharmaceuticals is PIRS.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 8/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/27/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/27/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.

All fundamentals about Pieris Pharmaceuticals

Our stock analysis for Pieris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pieris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.